Surgical outcomes with neoadjuvant therapy in resectable NSCLC (AEGEAN study)

Prof Dr David Harpole, a thoracic surgeon at Duke University Medical Center in Durham, North Carolina, was one of the researchers involved in the AEGEAN study. The study examined the effectiveness of neoadjuvant durvalumab and chemotherapy, followed by adjuvant durvalumab in treating resectable non-small cell lung cancer (NSCLC). At this year’s WCLC, the surgical outcomes and the outcomes in patients with resectable EGFR-mutated NSCLC were presented. Professor Harpole discussed the results and put the data into the perspective of clinical practice.

With the educational support of: